Heart failure with recovered ejection fraction

Yancy C, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240–327.

Punnoose L, Givertz M, Lewis E, et al. Heart failure with recovered ejection fraction: a distinct clinical entity. J Card Fail. 2011;17:527–32.

Basuray A, French B, Ky B, et al. Heart failure with recovered ejection fraction: clinical description, biomarkers and outcomes. Circulation. 2014;129:2380–7.

Ponikowski P, Voors A, Anker S, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2129–200.

Dunlay SM, Roger VL, Weston SA, et al. Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail. 2012;5:720–6.

Packer M, Antonopoulos GV, Berlin JA, et al. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am Heart J. 2001;141:899–907.

van Campen LC, Visser FC, Visser CA. Ejection fraction improvement by beta-blocker treatment in patients with heart failure: an analysis of studies published in the literature. J Cardiovasc Pharmacol. 1998;32(Suppl 1):S31–5.

Wake M, Yoshitomi H, Ito S, et al. Long-term echocardiographic follow-up of a patient with peripartum cardiomyopathy. J Cardiol Jpn Ed. 2012;7:91–5.

Kawahara H, Takahashi N, Yoshitomi H, et al. A breast cancer patient with chemotherapy-induced cardiomyopathy that was reversible with medical therapy. Shinzo. 2014;46:521–7.

Negishi T, Negishi K. Echocardiographic evaluation of cardiac function after cancer chemotherapy. J Echocardiogr. 2018;16:20–7.

D’Ambrosio A, Patti G, Manzoli A, et al. The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review. Heart. 2001;85:499–504.

Kramer DG, Trikalinos TA, Kent DM, et al. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol. 2010;56:392–406.

McNamara DM, Eikayam U, Alharethi R, et al. Clinical outcomes for peripartum cardiomyopathy in North America: results of the IPAC study (investigations of pregnancy-associated cardiomyopathy). J Am Coll Cardiol. 2015;66:905–14.

Wilcox JE, Fonarow GC, Yancy CW, et al. Factors associated with improvement in ejection fraction in clinical practice among patients with heart failure: findings from IMPROVE HF. Am Heart J. 2012;163:49–56.

Konstam MA. Reliability of ventricular remodeling as a surrogate for use in conjunction with clinical outcomes in heart failure. Am J Cardiol. 2005;96:867–71.

Kubanek M, Sramko M, Maluskova J, et al. Novel predictors of left ventricular reverse remodeling in individuals with recent-onset dilated cardiomyopathy. J Am Coll Cardiol. 2013;61:54–63.

Hellawell JL, Marqulies KB. Myocardial reverse remodeling. Cardiovasc Ther. 2012;30:172–81.

Sjoblom J, Muhrbeck J, Witt N, et al. Evolution of left ventricular ejection fraction after acute myocardial infarction: implications for implantable cardioverter-defibrillator eligibility. Circulation. 2014;130:743–8.

Camici PG, Prasad SK, Rimoldi OE. Stunning, hibernation, and assessment of myocardial viability. Circulation. 2008;117:103–14.

Giannuzzi P, Temporelli PL, Bosimini E, et al. Heterogeneity of left ventricular remodeling after acute myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico-3 Echo Substudy. Am Heart J. 2001;141:131–8.

Chaudhry FA, Tauke JT, Alessandrini RS, et al. Prognostic implications of myocardial contractile reserve in patients with coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol. 1999;34:730–8.

Lupon J, Gavidia-Bovadilla G, Ferrer E, et al. Dynamic trajectories of left ventricular ejection fraction in heart failure. J Am Coll Cardiol. 2018;72:591–601.

MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–7.

Greenberg B, Quinones MA, Koilpillai C, et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation. 1999;91:2573–81.

Wong M, Staszewsky L, Latini R, et al. Valsartan benefits left ventricular structure and function in heart failure: val-HeFT echocardiographic study. J Am Coll Cardiol. 2002;40:970–5.

Tsutamoto T, Wada A, Maeda K, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol. 2001;37:1228–33.

Ukkonen H, Beanlands RS, Burwash IG, et al. Effect of cardiac resynchronization on myocardial efficiency and regional oxidative metabolism. Circulation. 2003;107:28–31.

Hamdan MH, Zagrodzky JD, Joglar JA, et al. Biventricular pacing decreases sympathetic activity compared with right ventricular pacing in patients with depressed ejection fraction. Circulation. 2000;102:1027–32.

Basulay A, Fang JC. Management of patients with recovered systolic function. Prog Cardiovasc Dis. 2016;56:434–43.

Nabeta T, Inomata T, Ishii S, et al. Dilated cardiomyopathy with re-worsening left ventricular ejection fraction. Heart Vessels. 2018. https://doi.org/10.1007/s00380-018-1214-5